Stem cell therapy has been noted to be a disease-modifying treatment for Alzheimer’s disease (AD). After the failure to develop new drugs for AD, the number of studies on stem cells, such as mesenchymal stem cells (MSCs) and neural stem cells (NSCs), has increased from the early 2000 s. Issues pertaining to stem cells have been investigated in many animal studies in terms of stem cell origin, differentiation potency, method of culture, tumor formation, injection route, and mobility. Since 2010, mainly in East Asia, researchers began clinical trials investigating the use of stem cells for AD. Two phase I trials on moderate AD have been completed; though they revealed no severe acute or long-term side effects, no significant clinical efficacy was observed. Several studies, which involve more sophisticated study designs using different injection routes, well-established scales, and biomarkers such as amyloid positron emission tomography, are planned for mild to moderate AD patients. Here, we review the concept of stem cell therapy for AD and the progress of recent clinical trials.
PrinceMJ, WimoA, GuerchetMM, AliGC, WuY-T, PrinaM (2015) World Alzheimer’s Disease International. The Global Impact of Dementia.Alzheimer’s Disease International.
2.
PowersRE, AshfordJW, PeschinS (2008) . Alzheimer’s Foundation of America, AFA. Memory Matters. Alzheimer’s Foundation of America, AFA.
3.
BirksJ, HarveyR (2006) Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst RevCD001190.
LoyC, SchneiderL (2006) Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst RevCD001747.
6.
SchneiderLS, DagermanKS, HigginsJP, McShaneR (2011) Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol68, 991–998.
7.
KryscioRJ, AbnerEL, SchmittFA, GoodmanPJ, MendiondoM, Caban-HoltA, DennisBC, MathewsM, KleinEA, CrowleyJJ, SELECT Investigators (2013) A randomized controlled Alzheimer’s disease prevention trial’s evolution into an exposure trial: The PREADViSE TrialJ Nutr Health Aging17, 72–75.
8.
PetersR, BeckettN, ForetteF, TuomilehtoJ, ClarkeR, RitchieC, WaldmanA, WaltonI, PoulterR, MaS, ComsaM, BurchL, FletcherA, BulpittC, (2008) HYVET investigators Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): A double-blind, placebo controlled trialLancet Neurol7, 683–689.
9.
ADAPT Research Group, LyketsosCG, BreitnerJC, GreenRC, MartinBK, MeinertC, PiantadosiS, SabbaghM (2007) Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trialNeurology68, 1800–1808.
10.
DeKoskyST, WilliamsonJD, FitzpatrickAL, KronmalRA, IvesDG, SaxtonJA, LopezOL, BurkeG, CarlsonMC, FriedLP, KullerLH, RobbinsJA, TracyRP, WoolardNF, DunnL, SnitzBE, NahinRL, FurbergCD, Ginkgo Evaluation of Memory (GEM) Study Investigators (2008) Ginkgo biloba for prevention of dementia: A randomized controlled trialJAMA300, 2253–2262.
11.
VellasB, ColeyN, OussetPJ, BerrutG, DartiguesJF, DuboisB, GrandjeanH, PasquierF, PietteF, RobertP, TouchonJ, GarnierP, Mathiex-FortunetH, AndrieuS, GuidAge Study Group (2012) Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): A randomised placebo-controlled trialLancet Neurol11, 851–859.
12.
HardyJ, AllsopD (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s diseaseTrends Pharmacol Sci12, 383–388.
13.
PaulSA, SergeG, BrunoV, RichardB, DanielS, JulieL, DenisG (2007) Alzhemed: A potential treatment for Alzheimer’s diseaseCurr Alzheimer Res4, 473–478.
14.
SallowayS, SperlingR, KerenR, PorsteinssonAP, van DyckCH, TariotPN, GilmanS, ArnoldD, AbushakraS, HernandezC, CransG, LiangE, QuinnG, BairuM, PastrakA, CedarbaumJM, ELND005-AD201 Investigators (2011) A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer diseaseNeurology77, 1253–1262.
15.
GreenRC, SchneiderLS, AmatoDA, BeelenAP, WilcockG, SwabbEA, ZavitzKH, Tarenflurbil Phase 3 Study Group (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trialJAMA302, 2557–2564.
16.
DoodyRS, RamanR, FarlowM, IwatsuboT, VellasB, JoffeS, KieburtzK, HeF, SunX, ThomasRG, AisenPS, SiemersE, SethuramanG, MohsR, Semagacestat Study Group (2013) A phase 3 trial of semagacestat for treatment of Alzheimer’s diseaseN Engl J Med369, 341–350.
17.
CoricV, van DyckCH, SallowayS, AndreasenN, BrodyM, RichterRW, SoininenH, TheinS, ShiovitzT, PilcherG, ColbyS, RollinL, DockensR, PachaiC, PorteliusE, AndreassonU, BlennowK, SoaresH, AlbrightC, FeldmanHH, BermanRM (2012) Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer diseaseArch Neurol69, 1430–1440.
18.
SallowayS, SperlingR, GilmanS, FoxNC, BlennowK, RaskindM, SabbaghM, HonigLS, DoodyR, van DyckCH, MulnardR, BarakosJ, GreggKM, LiuE, LieberburgI, SchenkD, BlackR, GrundmanM, Bapineuzumab 201 Clinical Trial Investigators (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseNeurology73, 2061–2070.
DoodyRS, ThomasRG, FarlowM, IwatsuboT, VellasB, JoffeS, KieburtzK, RamanR, SunX, AisenPS, SiemersE, Liu-SeifertH, MohsR, Alzheimer’s Disease Cooperative Study Steering Committee, Solanezumab Study Group (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s diseaseN Engl J Med370, 311–321.
21.
DodelR, NeffF, NoelkerC, PulR, DuY, BacherM, OertelW (2010) Intravenous immunoglobulins as a treatment for Alzheimer’s disease: Rationale and current evidenceDrugs70, 513–528.
KileS, AuW, PariseC, RoseK, DonnelT, HankinsA, ChanM, GhassemiA (2015) IVIG treatment of mild cognitive impairment due to Alzheimer’s disease: A randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia.. J Neurol Neurosurg Psychiatry. doi: 10.1136/jnnp-2015-311486
26.
IlicD, PolakJM (2011) Stem cells in regenerative medicine: IntroductionBr Med Bull98, 117–126.
27.
TakahashiK, YamanakaS (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factorsCell126, 663–676.
MotheAJ, ZahirT, SantaguidaC, CookD, TatorCH (2011) Neural stem/progenitor cells from the adult human spinal cord are multipotent and self-renewing and differentiate after transplantation. PLoS One6, e27079.
33.
PangZP, YangN, VierbuchenT, OstermeierA, FuentesDR, YangTQ, CitriA, SebastianoV, MarroS, SüdhofTC, WernigM (2011) Induction of human neuronal cells by defined transcription factorsNature476, 220–223.
34.
LiuX, LiF, StubblefieldEA, BlanchardB, RichardsTL, LarsonGA, HeY, HuangQ, TanA-C, ZhangD, BenkeTA, SladekJR, ZahniserNR, LiCY (2012) Direct reprogramming of human fibroblasts into dopaminergic neuron-like cellsCell Res22, 321–332.
35.
RenfranzPJ, CunninghamMG, McKayRD (1991) Region-specific differentiation of the hippocampal stem cell line HiB5 upon implantation into the developing mammalian brainCell66, 713–729.
36.
LeeHJ, KimKS, KimEJ, ChoiHB, LeeKH, ParkIH, KoY, JeongSW, KimSU (2007) Brain transplantation of immortalized human neural stem cells promotes functional recovery in mouse intracerebral hemorrhage stroke modelStem Cells25, 1204–1212.
37.
LindvallO, KokaiaZ, Martinez-SerranoA (2004) Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat Med10, S42–S50.
38.
GoldmanS (2005) Stem and progenitor cell–based therapy of the human central nervous systemNat Biotechnol23, 862–871.
39.
KimSU, De VellisJ (2009) Stem cell-based cell therapy in neurological diseases: A reviewJ Neurosci Res87, 2183–2200.
40.
DivyaMS, RoshinGE, DivyaTS, RasheedVA, SanthoshkumarTR, ElizabethKE, JamesJ, PillaiRM (2012) Umbilical cord blood-derived mesenchymal stem cells consist of a unique population of progenitors co-expressing mesenchymal stem cell and neuronal markers capable of instantaneous neuronal differentiation. Stem Cell Res Ther3, 57.
41.
FriedensteinA, Piatetzky-ShapiroI, PetrakovaK (1966) Osteogenesis in transplants of bone marrow cellsDevelopment16, 381–390.
42.
NoortW, ScherjonS, Kleijburg-Van Der KeurC, KruisselbrinkA, Van BezooijenR, BeekhuizenW, WillemzeR, KanhaiH, FibbeW (2003) Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potentialHaematologica88, 845–852.
43.
ChengH, JiangW, PhillipsFM, HaydonRC, PengY, ZhouL, LuuHH, AnN, BreyerB, VanichakarnP, SzatkowskiJP, ParkJY, HeTC (2003) Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs)J Bone Joint Surg Am85, 1544–1552.
44.
HuY, LiaoL, WangQ, MaL, MaG, JiangX, ZhaoRC (2003) Isolation and identification of mesenchymal stem cells from human fetal pancreasJ Lab Clin Med141, 342–349.
45.
RomanovYA, SvintsitskayaVA, SmirnovVN (2003) Searching for alternative sources of postnatal human mesenchymal stem cells: Candidate MSC-like cells from umbilical cordStem Cells21, 105–110.
PountosI, GiannoudisPV (2005) Biology of mesenchymal stem cells. Injury36, S8–S12.
48.
ZaherW, HarknessL, JafariA, KassemM (2014) An update of human mesenchymal stem cell biology and their clinical usesArch Toxicol88, 1069–1082.
49.
SacchettiB, FunariA, MichienziS, Di CesareS, PiersantiS, SaggioI, TagliaficoE, FerrariS, RobeyPG, RiminucciM, BiancoP (2007) Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironmentCell131, 324–336.
50.
ChangKA, LeeJH, SuhYH (2014) Therapeutic potential of human adipose-derived stem cells in neurological disordersJ Pharmacol Sci126, 293–301.
51.
CookD, GeneverP (2013) Regulation of mesenchymal stem cell differentiation. In Transcriptional and Translational Regulation of Stem Cells, Springer, pp. 213–229.
52.
LeeJK, JinHK, BaeJS (2009) Bone marrow-derived mesenchymal stem cells reduce brain amyloid-β deposition and accelerate the activation of microglia in an acutely induced Alzheimer’s disease mouse modelNeurosci Lett450, 136–141.
53.
BabaeiP, Soltani TehraniB, AlizadehA (2012) Transplanted bone marrow mesenchymal stem cells improve memory in rat models of Alzheimer’s diseaseStem Cells Int2012, 369417.
54.
LeeHJ, LeeJK, LeeH, CarterJE, ChangJW, OhW, YangYS, SuhJ-G, LeeB-H, JinHK, BaeJS (2012) Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer’s disease mouse model through modulation of neuroinflammationNeurobiol Aging33, 588–602.
55.
YunH, KimH, ParkK, ShinJ, KangA, il LeeK, SongS, KimY, HanS, ChungH, HongJT (2013) Placenta-derived mesenchymal stem cells improve memory dysfunction in an Aβ1–42-infused mouse model of Alzheimer’s disease. Cell Death Dis4, e958.
56.
KellyS, BlissT, ShahA, SunG, MaM, FooW, MaselJ, YenariM, WeissmanI, UchidaN, PalmerT, SteinbergGK (2004) Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortexProc Natl Acad Sci U S A101, 11839–11844.
57.
EinsteinO, Ben-Menachem-TzidonO, Mizrachi-KolR, ReinhartzE, GrigoriadisN, Ben-HurT (2006) Survival of neural precursor cells in growth factor-poor environment: Implications for transplantation in chronic diseaseGlia53, 449–455.
58.
EinsteinO, Ben-HurT (2008) The changing face of neural stem cell therapy in neurologic diseasesArch Neurol65, 452–456.
59.
PluchinoS, QuattriniA, BrambillaE, GrittiA, SalaniG, DinaG, GalliR, Del CarroU, AmadioS, BergamiA, FurlanR, ComiG, VescoviAL, MartinoG (2003) Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosisNature422, 688–694.
60.
BurgessA, Ayala-GrossoCA, GangulyM, JordãoJF, AubertI, HynynenK (2011) Targeted delivery of neural stem cells to the brain using MRI-guided focused ultrasound to disrupt the blood-brain barrier. PloS One6, e27877.
61.
AleynikA, GernavageKM, MouradY, ShermanLS, LiuK, GubenkoYA, RameshwarP (2014) Stem cell delivery of therapies for brain disordersClin Transl Med3, 24.
62.
RaJC, ShinIS, KimSH, KangSK, KangBC, LeeHY, KimYJ, JoJY, YoonEJ, ChoiHJ, KwonE (2011) Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humansStem Cells Dev20, 1297–1308.
63.
KimS, ChangK-A, ParkH-G, RaJC, KimH-S, SuhYH (2012) The preventive and therapeutic effects of intravenous human adipose-derived stem cells in Alzheimer’s disease mice. PLoS One7, e45757.
64.
LiW, JinR, HuX (2012) Migration of PKH26-labeled mesenchymal stem cells in rats with Alzheimer’s diseaseZhejiang Da Xue Xue Bao Yi Xue Ban41, 659–664.
65.
LeeHJ, LeeJK, LeeH, ShinJ-w, CarterJE, SakamotoT, JinHK, BaeJS (2010) The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer’s diseaseNeurosci Lett481, 30–35.
66.
WangQ, MatsumotoY, ShindoT, MiyakeK, ShindoA, KawanishiM, KawaiN, TamiyaT, NagaoS (2006) Neural stem cells transplantation in cortex in a mouse model of Alzheimer’s diseaseJ Med Invest53, 61–69.
67.
MoghadamFH, AlaieH, KarbalaieK, TanhaeiS, EsfahaniMHN, BaharvandH (2009) Transplantation of primed or unprimed mouse embryonic stem cell-derived neural precursor cells improves cognitive function in Alzheimerian ratsDifferentiation78, 59–68.
68.
ParkD, JooSS, KimTK, LeeSH, KangH, LeeHJ, LimI, MatsuoA, TooyamaI, KimYB, KimSU (2012) Human neural stem cells overexpressing choline acetyltransferase restore cognitive function of kainic acid-induced learning and memory deficit animalsCell Transplant21, 365–371.
69.
ParkD, LeeHJ, JooSS, BaeD-K, YangG, YangY-H, LimI, MatsuoA, TooyamaI, KimYB, KimSU (2012) Human neural stem cells over-expressing choline acetyltransferase restore cognition in rat model of cognitive dysfunctionExp Neurol234, 521–526.
70.
BalesKR, TzavaraET, WuS, WadeMR, BymasterFP, PaulSM, NomikosGG (2006) Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibodyJ Clin Invest116, 825–832.
71.
IwataN, TsubukiS, TakakiY, ShirotaniK, LuB, GerardNP, GerardC, HamaE, LeeHJ, SaidoTC (2001) Metabolic regulation of brain Abeta by neprilysinScience292, 1550–1552.
72.
FarrisW, MansourianS, ChangY, LindsleyL, EckmanEA, FroschMP, EckmanCB, TanziRE, SelkoeDJ, GuénetteS (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad SciU S A100, 4162–4167.
73.
MillerBC, EckmanEA, SambamurtiK, DobbsN, ChowKM, EckmanCB, HershLB, ThieleDL (2003) Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci U S A100, 6221–6226.
74.
MelchorJP, PawlakR, StricklandS (2003) The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-β (Aβ) degradation and inhibits Aβ-induced neurodegenerationJ Neurosci23, 8867–8871.
75.
Mueller-SteinerS, ZhouY, AraiH, RobersonED, SunB, ChenJ, WangX, YuG, EspositoL, MuckeL, GanL (2006) Antiamyloidogenic and neuroprotective functions of cathepsin B: Implications for Alzheimer’s diseaseNeuron51, 703–714.
76.
MarrRA, RockensteinE, MukherjeeA, KindyMS, HershLB, GageFH, VermaIM, MasliahE (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic miceJ Neurosci23, 1992–1996.
77.
KohS-H, KimKS, ChoiMR, JungKH, ParkKS, ChaiYG, RohW, HwangSJ, KoH-J, HuhYM, KimHT, KimSH (2008) Implantation of human umbilical cord-derived mesenchymal stem cells as a neuroprotective therapy for ischemic stroke in ratsBrain Res1229, 233–248.
78.
LeeHJ, LimIJ, ParkSW, KimYB, KoY, KimSU (2012) Human neural stem cells genetically modified to express human nerve growth factor (NGF) gene restore cognition in the mouse with ibotenic acid-induced cognitive dysfunctionCell Transplant21, 2487–2496.
79.
Blurton-JonesM, KitazawaM, Martinez-CoriaH, CastelloNA, MüllerF-J, LoringJF, YamasakiTR, PoonWW, GreenKN, LaFerlaFM (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer diseaseProc Natl Acad Sci U S A106, 13594–13599.
80.
XuanA, LongD, GuH, YangD, HongL, LengS (2008) BDNF improves the effects of neural stem cells on the rat model of Alzheimer’s disease with unilateral lesion of fimbria-fornixNeurosci Lett440, 331–335.
81.
YangH, XieZ, WeiL, YangH, YangS, ZhuZ, WangP, ZhaoC, BiJ (2013) Human umbilical cord mesenchymal stem cell-derived neuron-like cells rescue memory deficits and reduce amyloid-beta deposition in an AβPP/PS1 transgenic mouse modelStem Cell Res Ther4, 76.
82.
WalkerD, LueLF (2005) Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer’s disease and other neurodegenerative diseasesJ Neurosci Res81, 412–425.
83.
KimSU, de VellisJ (2005) Microglia in health and diseaseJ Neurosci Res81, 302–313.
84.
BardF, CannonC, BarbourR, BurkeR-L, GamesD, GrajedaH, GuidoT, HuK, HuangJ, Johnson-WoodK, KhanK, KholodenkoD, LeeM, LieberburgI, MotterR, NguyenM, SorianoF, VasquezN, WeissK, WelchB, SeubertP, SchenkD, YednockT (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer diseaseNat Med6, 916–919.
85.
LiuY, WalterS, StagiM, ChernyD, LetiembreM, Schulz-SchaefferW, HeineH, PenkeB, NeumannH, FassbenderK (2005) LPS receptor (CD14): A receptor for phagocytosis of Alzheimer’s amyloid peptideBrain128, 1778–1789.
86.
MalmTM, KoistinahoM, PärepaloM, VatanenT, OokaA, KarlssonS, KoistinahoJ (2005) Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to β-amyloid deposition in APP/PS1 double transgenic Alzheimer miceNeurobiol Dis18, 134–142.
87.
RogersJ, LueLF (2001) Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer’s diseaseNeurochem Int39, 333–340.
88.
RogersJ, StrohmeyerR, KovelowskiC, LiR (2002) Microglia and inflammatory mechanisms in the clearance of amyloid β peptideGlia40, 260–269.
89.
NguyenMD, JulienJ-P, RivestS (2002) Innate immunity: The missing link in neuroprotection and neurodegeneration?Nat Rev Neurosci3, 216–227.
90.
LeeJK, JinHK, EndoS, SchuchmanEH, CarterJE, BaeJS (2010) Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer’s disease mice by modulation of immune responsesStem Cells28, 329–343.
91.
KimK-S, KimHS, ParkJ-M, KimHW, ParkM-k, LeeH-S, LimDS, LeeTH, ChoppM, MoonJ (2013) Long-term immunomodulatory effect of amniotic stem cells in an Alzheimer’s disease modelNeurobiol Aging34, 2408–2420.
92.
KimHJ, SeoSW, ChangJW, LeeJI, KimCH, ChinJ, ChoiSJ, KwonH, YunHJ, LeeJM, KimST, ChoeYS, LeeK-H, NaDL (2015) Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: A phase 1 clinical trialAlzheimers Dement (N Y)1, 95–102.
93.
LaluMM, McIntyreL, PuglieseC, FergussonD, WinstonBW, MarshallJC, GrantonJ, StewartDJ, Canadian Critical Care Trials Group (2012) Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. PLoS One7, e47559.
94.
LeeJS, HongJM, MoonGJ, LeePH, AhnYH, BangOY (2010) A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic strokeStem Cells28, 1099–1106.
